Concepedia

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

Peter A. Calabresi, Ernst-Wilhelm Radüe, Douglas S. Goodin, Douglas Jeffery, Kottil Rammohan, Anthony T. Reder, Timothy Vollmer, Mark Agius, Ludwig Kappos, Tracy Stites,

The Lancet Neurology · 2014 · 822 citations · 9 references

DOI

Concepts

References

9

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.9K citations

, , +14

Defining the clinical course of multiple sclerosis

Fred Lublin, Stephen C. Reingold · Neurology · 1996 · 3.7K citations

, , +17

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

Ludwig Kappos, Ernst‐Wilhelm Radue, Paul O’Connor et al. · New England Journal of Medicine · 2010 · 2.6K citations · Full text

, , +14

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2010 · 2.2K citations · Full text

, , +15

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P <sub>1</sub> ) modulation

Ji Woong Choi, Shannon E. Gardell, Deron R. Herr et al. · Proceedings of the National Academy of Sciences · 2010 · 578 citations · Full text

, , +17